SubHero Banner

Xarelto® (rivaroxaban) – New indication

October 14, 2019 - Janssen announced the FDA approval of Xarelto (rivaroxaban), for the prophylaxis of venous thromboembolism (VTE) and VTE related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and not at high risk of bleeding.

Download PDF